Radiation therapy in the management of giant lymph node hyperplasia

Sethi, Tejinder; Joshi, Kusum; Sharma, Shanu; Gupta, Bhumika

doi:10.1259/0007-1285-63-752-648

Cited by 27 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of interest, nonsystemic therapies yielded good results in five of six multicentric CD patients so treated. There have been reports in the literature of a localized treatment approach resulting in distant response [37, 49–51]. None of the patients in this series had high‐dose chemotherapy with autologous stem cell transplant given the timeframe of ascertainment of cases.…”

Section: Disscussionmentioning

confidence: 99%

The clinical spectrum of Castleman's disease

et al. 2012

View full text Add to dashboard Cite

Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10‐year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5‐year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study. Am. J. Hematol. 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Disscussionmentioning

confidence: 99%

The clinical spectrum of Castleman's disease

et al. 2012

View full text Add to dashboard Cite

show abstract

“…As a result, the prevailing medical opinion became that radiotherapy was ineffective in the treatment of Castleman disease. Nevertheless, several case reports20–27 and retrospective studies28 have documented favorable responses to radiotherapy in both unicentric and multicentric Castleman disease.…”

mentioning

confidence: 99%

Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy

Chronowski

Wilder

et al. 2001

Cancer

274

237

View full text Add to dashboard Cite

BACKGROUND Although surgery is considered standard therapy for unicentric Castleman disease, favorable responses to radiotherapy also have been documented. The authors undertook this study to analyze the clinical factors, treatment approaches, and outcomes of patients with unicentric or multicentric Castleman disease, and to report the outcomes of patients with unicentric Castleman disease treated with radiotherapy. METHODS The authors reviewed the medical records of 22 patients who had received a histologic diagnosis of Castleman disease at the University of Texas M. D. Anderson Cancer Center between 1988 and 1999. One patient with a concurrent histopathologic diagnosis of nonsecretory multiple myeloma was excluded from the study. In all patients, the diagnosis of Castleman disease was based on the results of lymph node biopsies. Disease was categorized as being either unicentric or multicentric and further subdivided into hyaline vascular, plasma cell, or mixed variant histologic types. Clinical variables and outcomes were analyzed according to treatment, which consisted of surgery, chemotherapy, or radiotherapy. RESULTS Records from 21 patients were analyzed: 12 had unicentric disease, and 9 had multicentric disease. The mean follow‐up time for the entire series was 51 months (median, 40 months). Four patients with unicentric disease were treated with radiotherapy alone: 2 remain alive and symptom free, 2 died of causes unrelated to Castleman disease and had no evidence of disease at last follow‐up. Eight patients with unicentric disease were treated with complete or partial surgical resection, and all are alive and asymptomatic. All nine patients with multicentric disease were treated with combination chemotherapy: five are alive with no evidence of disease, and four are alive with progressive disease. CONCLUSIONS Surgery results in excellent rates of cure in patients with unicentric Castleman disease; radiotherapy can also achieve clinical response and cure in selected patients. Multicentric Castleman disease is a more aggressive clinical entity and is most effectively treated with combination chemotherapy, whereas the role of radiotherapy in its treatment remains unclear. Cancer 2001;92:670–6. © 2001 American Cancer Society.

show abstract

“…Radiation therapy has also been used to treat Castleman disease 2,3,5,33–36 . Keller et al studieded four patients treated with radiation, in whom there was no clinical response 2 .…”

Section: Discussionmentioning

confidence: 99%

“…5,13,[26][27][28][29][30][31][32] Radiation therapy has also been used to treat Castleman disease. 2,3,5,[33][34][35][36] Keller et al studieded four patients treated with radiation, in whom there was no clinical response. 2 However, Chronowski et al described 12 patients with unicentric Castleman disease of type, 4 of whom were treated with radiation alone; 3 had a complete response.…”

Section: Managementmentioning

confidence: 99%